Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 May 3;336(7651):999-1003.
doi: 10.1136/bmj.39524.439618.25. Epub 2008 Apr 3.

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

Affiliations
Randomized Controlled Trial

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

Ted J Kaptchuk et al. BMJ. .

Abstract

Objective: To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components.

Design: A six week single blind three arm randomised controlled trial.

Setting: Academic medical centre.

Participants: 262 adults (76% women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of > or =150 on the symptom severity scale.

Interventions: For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient-practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks.

Main outcome measures: Global improvement scale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life.

Results: At three weeks, scores on the global improvement scale were 3.8 (SD 1.0) v 4.3 (SD 1.4) v 5.0 (SD 1.3) for waiting list versus "limited" versus "augmented," respectively (P<0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28% on waiting list, 44% in limited group, and 62% in augmented group (P<0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P<0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P<0.001). All pairwise comparisons between augmented and limited patient-practitioner relationship were significant: global improvement scale (P<0.001), adequate relief of symptoms (P<0.001), symptom severity score (P=0.007), quality of life (P=0.01). Results were similar at six week follow-up.

Conclusion: Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient-practitioner relationship is the most robust component.

Trial registration: Clinical Trials NCT00065403.

PubMed Disclaimer

Figures

None
Fig 1 Flow of participants through study
None
Fig 2 Outcomes at three week end point
None
Fig 3 Outcomes at six week follow-up

Comment in

References

    1. Kaptchuk TJ. Powerful placebo: the dark side of the randomized controlled trial. Lancet 1998;351:1722-5. - PubMed
    1. Hrobjartsson A. What are the main methodological problems in the estimation of placebo effects. J Clin Epidemiol 2002;55:430-5. - PubMed
    1. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. J Roy Soc Med 2008. (in press). - PMC - PubMed
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-91. - PubMed
    1. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92:1282-4. - PubMed

Publication types

Associated data